Zantac found to be potential cancer risk by FDA due to NDMA Carcinogen
This page features: Cited Research Articles The FDA announced on September 13, 2019, that low levels of a probable human carcinogen called N-nitrosodimethlylamine (NDMA), are found in Zantac (ranitidine). Then, on January 8, 2020, the FDA alerted patients and health care professionals of two voluntary recalls of the drug known by the name of Zantac (ranitidine) …
Zantac found to be potential cancer risk by FDA due to NDMA Carcinogen Read More »